These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29725684)

  • 1. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.
    Liu Y; Zhao G; Xu CF; Luo YL; Lu ZD; Wang J
    Biomater Sci; 2018 May; 6(6):1592-1603. PubMed ID: 29725684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted disruption of the
    Zeng J; Liang X; Duan L; Tan F; Chen L; Qu J; Li J; Li K; Luo D; Hu Z
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):525-537. PubMed ID: 38414349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
    García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
    Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
    Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
    J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
    Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
    CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells.
    Jiang G; Huang Z; Yuan Y; Tao K; Feng W
    J Hematol Oncol; 2021 Sep; 14(1):139. PubMed ID: 34488814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation.
    Liu Y; Cao ZT; Xu CF; Lu ZD; Luo YL; Wang J
    Biomaterials; 2018 Jul; 172():92-104. PubMed ID: 29723758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-
    Singh A; Bhatia P
    Curr Gene Ther; 2021; 21(3):270-277. PubMed ID: 33596804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected
    Vuelta E; Ordoñez JL; Sanz DJ; Ballesteros S; Hernández-Rivas JM; Méndez-Sánchez L; Sánchez-Martín M; García-Tuñón I
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
    Peng C; Li S
    Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
    Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
    Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.
    He Q; Dong J; Zhen H; Ying Y; Zhang J; Li Q; Li B; Zhou Y
    Leuk Res; 2011 Aug; 35(8):1074-9. PubMed ID: 21163528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
    Lund HL; Hughesman CB; McNeil K; Clemens S; Hocken K; Pettersson R; Karsan A; Foster LJ; Haynes C
    Anal Bioanal Chem; 2016 Feb; 408(4):1079-94. PubMed ID: 26631023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
    Furukawa Y; Ju SL; Cho HL; Tatsumi N
    Osaka City Med J; 1993 Jun; 39(1):35-45. PubMed ID: 7694218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.